Agilvax

Agilvax is an immunotherapy company utilizing its proprietary virus-like particle (VLP) platform technology to enable the body’s immune system to fight disease.  Our lead indications are focused on oncology and infectious diseases impacting global populations, with broad applicability across therapeutic areas.

Focus area
Immunology
Commencement date
04/16/2018